You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a blood fatty acid-based algorithm as an early predictor of insulin resistance: Applying machine learning to harmonized data from prospective cohort studies

    SBC: OMEGAQUANT ANALYTICS, LLC.            Topic: 200

    Project Summary Metabolic diseases, such as Metabolic Syndrome (MetSyn) and type 2 diabetes (T2DM) affect ~37% and ~10% of Americans, respectively, with a substantial impact on the health, quality of life and financial security of these individuals. Without the means to identify high risk individuals conveniently and cheaply, many will find care too little and too late: more than 80% of individual ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy

    SBC: SAB Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Abstract Currently available anti thymocyte globulinATGproducts are polyclonal animal antibodiesATGAMequine polyclonal ATGThymoglobulinrabbit polyclonal ATGand have found broad use as immune tolerizing agentsparticularly for induction therapy in a majority of tissue transplantsfor acute transplant rejectionand as treatment for graft vshost disease following bone marrow transplantsE ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Advancing a Candidate Human Polyclonal Anti-Thymocyte Globulin Product Produced in Transchromosomal Bovine for Transplant Induction/Acute Rejection and T1D Therapy

    SBC: SAB Biotherapeutics, Inc.            Topic: NIAID

    Currently available anti-thymocyte globulin (ATG) products are polyclonal animal antibodies (ATGAM – equine polyclonal ATG, Thymoglobulin – rabbit polyclonal ATG) and have found broad use as immune tolerizing agents, particularly for induction therapy in a majority of tissue transplants, for acute transplant rejection, and as treatment for graft vs. host disease following bone marrow transplan ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Multi-release drug-coated balloons for the treatment of peripheral artery disease with long, diffuse, and multiple lesions

    SBC: Tailored Medical Devices Inc.            Topic: NHLBI

    Project Summary Abstract Peripheral artery diseasePADaffects overmillion people worldwide and can result in life threating complicationsCurrentlydrug coated balloonsDCBsare used to treat lesions in the peripheral arteriesHowevercommercially available DCBs are designed to treat only a single blockage siteIn PAD patientscomplex lesions involving longdiffuseand or multiple blockages are often found r ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a STAT2 knock-out hamster model for wild-type filovirus infections

    SBC: Auratus Bio LLC            Topic: 200

    DESCRIPTION provided by applicant Golden Syrian hamsters offer certain advantages over the use of other rodents in the study of a number of human diseases In the context of cancer research the histological and cytogenetic changes in the development of pancreatic cancers are similar in humans and hamsters but not in mice Hamsters are also the model species of choice for studying oncolytic ad ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Production of therapeutic human polyclonal antibodies against influenza viruses

    SBC: SAB Biotherapeutics, Inc.            Topic: R

    DESCRIPTION provided by applicant A research plan is proposed to produce potent human polyclonal antibodies against influenza viruses by immunizing genetically modified bovines with seasonal influenza vaccine in combination with a strong adjuvant and immune stimulator Previous studies have demonstrated that genetically engineered bovines are capable of producing large amounts of human polyclo ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Potent and Safe Antimicrobial Prosthetic Liner to Control Odor & Reduce Infection for Lower Limb Amputees

    SBC: Antimicrobial Materials, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Silicone roll on prosthetic liners are widely used by lower limb amputees Most patients however complain of skin related issues due to the warm moist environment The long term goal of this SBIR project is to develop and commercialize a vastly improved silicone prosthetic liner with antimicrobial properties so as to improve hygiene and greatly reduce risk of ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. IGF::OT::IGF- DEVELOPMENT OF INULIN ACETATE-BASED ADJUVANT.

    SBC: VST LLC            Topic: NIAID

    This project aims to evaluate and compare a new soluble inulin microparticle adjuvant along with approved human adjuvants alum and ISA-51VG (Seppic) in a vaccine study utilizing the company?s Rift Valley Fever virus (RVFV) recombinant protein subunit vaccine. The new adjuvant may have potential commercial applications for both human and veterinary vaccines for Rift Valley Fever. PUBLIC HEALTH RELE ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Label-free platform for applications in drug discovery

    SBC: VST LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The primary sequelae resulting from radical mastectomy and sentinel lymph node removal during the treatment of breast cancer is the development of lymphedema in related limbs. Estimates of the frequency of post-cancer lymphedema range from 20%-90%, depending upon the metrics used to measure development of the condition. There is significant social and monetary ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Antibacterial, antifungal, antiviral, and antispore paints

    SBC: Prairie Scientific Innovations            Topic: NINR

    DESCRIPTION (provided by applicant): There is a fast growing need for antimicrobial paints and coatings to improve microbial quality in residential, commercial, institutional, and industrial applications so as to control the growth of mold and/or reduce the risk of healthcare-associated infections or community-acquired infections. A number of paint products on the market claim antimicrobial func ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government